Active substance

Results for the substance tislelizumab

1 result

About this active substance

Tislelizumab is a monoclonal antibody used to treat certain cancers in adults. It belongs to the anti-PD-1 immunotherapy class and may be used, depending on the country and tumour characteristics, in lung cancer, oesophageal squamous cell cancer, gastric or gastro-oesophageal junction cancer, nasopharyngeal cancer and other advanced oncology settings.

The medicine helps the immune system recognise and attack cancer cells by blocking the PD-1 signal, which can switch off T cells. It may be given alone or with chemotherapy. The expected benefit depends on the cancer type, stage, previous treatments and sometimes on the level of PD-L1 expression in the tumour.

Tislelizumab is given as an intravenous infusion, usually every few weeks, under the supervision of an oncologist. Blood tests and checks of liver, kidney and hormone gland function are done before and during treatment. Doses may be delayed, or treatment stopped, if important side effects occur.

Possible side effects include tiredness, nausea, cough, diarrhea, rash, loss of appetite and infections. Because it activates the immune system, it can inflame the lungs, bowel, liver, kidneys, skin or hormone glands. Contact your doctor promptly for fever, shortness of breath, severe diarrhea, yellow skin or eyes, or abdominal pain.